Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week Open-label Long-term Safety Study of SEP-363856 in Schizophrenia (Japan)
jRCT2031220039Completed
- Sponsor
- Sumitomo Pharma
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ulotaront in schizophrenia, sponsored by Sumitomo Pharma. Started May 2022; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2031220039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220039.